Are leukotrienes or PAF involved in hyperbaric oxygen toxicity?

Area of Science:

• Pharmacology
• Toxicology
• Biochemistry

Background:

• Hyperbaric oxygen (HBO) therapy can cause toxicity, characterized by convulsions and lung damage.
• Leukotrienes and platelet-activating factor (PAF) are implicated in inflammatory and toxic responses.
• Targeting these pathways may offer a protective strategy against HBO toxicity.

Purpose of the Study:

• To evaluate the efficacy of selective leukotriene and PAF inhibitors against hyperbaric oxygen toxicity.
• To determine if these inhibitors can prevent HBO-induced convulsions and pulmonary damage in vivo.

Main Methods:

• In vivo testing of leukotriene D4 (L660771), 5-lipoxygenase pathway (L663536), PAF antagonist (L659989), and leukotriene B4 (LTB4) antagonist (SC-41930).
• Assessment of protection against hyperbaric oxygen-induced (515-615 kPa) convulsions and lung damage in rats and mice.

Main Results:

• L660771 and L663536 did not affect HBO toxicity.
• L659989 provided marginal protection against convulsions but not lung damage.
• SC-41930 effectively inhibited HBO-induced convulsions in both species.
• SC-41930 significantly protected rats against pulmonary toxicity, with marginal effects in mice.

Conclusions:

• The LTB4 antagonist SC-41930 demonstrates significant potential for preventing hyperbaric oxygen toxicity, particularly convulsions and pulmonary damage in rats.
• The differential efficacy observed between rats and mice suggests species-specific mechanisms in hyperbaric oxygen toxicity.
• Targeting the LTB4 pathway warrants further investigation for therapeutic applications in managing oxygen toxicity.